Inactive Instrument

PCAS Share Price

PCA

FR0000053514

PCAS specializes in developing, manufacturing, and marketing fine and specialty chemicals. Sales are distributed by family of products as follows: - synthesized pharmaceutical products (63.5%); - fine chemicals (36.5%): technical fluids and additives for the lubricant industry, chemical additive synthesis. The group also offers photochemical and new technology products (photosensitive materials, photo-initiators, and polymers for photography, reprography, and micro-electronics). At the end of 2022, the group had 7 production sites located in France (5), Canada and Finland. France accounts for 76% of net sales.

Employees

1,178

Sector

Pharmaceuticals

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

09/24/09	Orapi: takeover bid reopens on February 12
02/24/02	Orapi: 3.15 million shares tendered to the takeover bid
22/23/22	Orapi: takeover bid opens on December 27
18/23/18	PCAS: 200 ME capital increase
03/23/03	PCAS: OPAS to start this Friday
24/23/24	PCAS Announces the Consolidated Net Sales Results for the Month of September 30, 2023	CI
16/23/16	Progyny, Inc. : Want to have a baby?
07/23/07	PCAS: Seqens launches minority share offer
06/23/06	PCAS SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/23/27	PCAS SA Reports Consolidated Sales Results for the Period Ended June 30, 2023	CI
01/23/01	DIC Corporation completed the acquisition of PCAS Canada Inc. from PCAS SA.	CI
25/23/25	PCAS: sale of Canadian subsidiary confirmed
25/23/25	PCAS to Divest Canadian Arm to Japan's DIC	MT

24/23/24	PCAS: Net Sales as of September 30, 2023	GL
06/23/06	PCAS: RESULTS AS OF JUNE 30, 2023	GL
27/23/27	Pcas: Net sales as of June 30, 2023	GL
25/23/25	PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation	GL
02/23/02	PCAS enters into exclusive negotiations with DIC Corporation following receipt of an offer for the acquisition of its Canadian subsidiary, PCAS Canada Inc.	GL

09/24/09	Orapi : l'OPA réouvre le 12 février
02/24/02	Orapi : 3,15 millions d'actions apportées à l'OPA
05/24/05	Progyny, Inc.: ¿Quieres tener un bebé?
22/23/22	Orapi : l'OPA démarre le 27 décembre
18/23/18	PCAS : augmentation de capital de 200 ME

Manager	Title	Age	Since
Gildas Barreyre CEO	Chief Executive Officer	43	03/05/2025
Eric Moissenot DFI	Director of Finance/CFO	-	-
Gérard Guillamot CTO	Chief Tech/Sci/R&D Officer	-	01/03/1999

Director	Title	Age	Since
Jacqueline Lecourtier BRD	Director/Board Member	74	01/03/2014
Janine Cossy BRD	Director/Board Member	-	-

PCAS Share Price

Stocks

PCA

FR0000053514

Pharmaceuticals

Latest news : PCAS

Press Releases: PCAS

News in other languages: PCAS

Managers and Directors: PCAS

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCAS	-.--%	-.--%	-	-	12Cr
ELI LILLY AND COMPANY	+1.86%	+7.65%	+55.77%	+158.84%	1,08200Cr
JOHNSON & JOHNSON	+3.57%	+7.42%	+69.09%	+58.92%	63TCr
ABBVIE INC.	+3.99%	+7.37%	+36.87%	+93.77%	46TCr
ROCHE HOLDING AG	+3.86%	+1.85%	+31.30%	+24.86%	34TCr
ASTRAZENECA PLC	-0.56%	+2.80%	+39.13%	+28.20%	30TCr
NOVARTIS AG	-0.08%	+1.52%	+29.96%	+42.13%	29TCr
NOVO NORDISK A/S	-1.54%	+3.56%	-25.96%	-40.53%	23TCr
AMGEN INC.	+3.55%	+6.05%	+26.04%	+68.52%	20TCr
GILEAD SCIENCES, INC.	+4.21%	+6.00%	+17.72%	+70.33%	16TCr
Average	+1.89%	+4.92%	+31.10%	+56.12%	41.11TCr
Weighted average by Cap.	+2.24%	+5.54%	+41.79%	+80.52%